In clinical research, determining sample size plays an important role. A cross-over design (CD) is widely used to compare multiple groups in order to verify the statistical significance of mean difference among multiple groups, because it has an advantage of removing any factors caused by subject variability. When multi-omics data such as metabolomics data is analysed, we often adopt CD to identify biomarkers that have group effects. While some methods exist for determining the sample size when comparing two groups, no available method allows comparison of more than two treatment groups. In this research, we propose a novel method for determining the sample size of CD with multiple treatment groups. We first propose a method for testing single biomarkers and then a method for a large number of biomarkers while controlling the false discovery rate or the family wise error rate.
Introduction
Determining sample size is important in clinical research (Wang and Chow, 2007) . In order to confirm the validity and success of an intended trial, a sufficient number of patients is crucial. Also, the larger the sample size, the greater the precision and power for a given study design to detect a treatment effect (Kasiulevičius et al., 2006) . However, due to the high cost and other difficulties of recruiting subjects for certain clinical trials, it is essential to determine the optimal sample size n.
In a cross-over design (CD), one subject is randomly assigned to a certain sequence and is sequentially treated for various groups. There are many types of CDs available for the given group number. For computational convenience, orthogonal CDs are most commonly used (Jones and Kenward, 2014) . Table 1 shows the orthogonal design for a three-group comparison; Table 2 shows a four-group comparison. In a parallel design, on the other hand, each experimental unit is randomly assigned to receive only one experimental group. A two sample t-test and analysis of variance are representative examples of parallel designs. The random allocation of each subject to a sequence of experimental treatments in CDs distinguishes it from such parallel designs. It thus has the advantage over parallel designs of removing any component caused by differences between subjects (Jones and Kenward, 2014) . Data from CDs are correlated among response values by subject. Linear mixed effect models (LMMs) are commonly used to analyse the data from CDs. Table 1 Example of cross-over design with three treatments
Period 1 Period 2 Period 3
Sequence 1 In CDs, sample size is determined by the number of subjects recruited for clinical trials. In this paper, the sample size is the number of subjects needed for each sequence. Here, we only treat a well-balanced case in which the same number of subjects are randomly assigned to every sequence. Wang and Chow (2007) proposed a method for determining sample size for CD with two treatments using a power function based on t test statistics. Because this method checks the mean difference between two treatments, it is difficult to apply to CDs with more than three treatments. Extending this method, we propose a new approach to calculating sample size for CDs in the case of multiple groups. In many cases, researchers measure many biomarkers in one experiment and test whether they are statistically significant or not. Testing all measured markers simultaneously causes a multiple comparison problem. If we reject null hypotheses with the significant level α in each test, then overall type 1 error exceeds α (Wang and Chow, 2007) . Two methods have been widely used to avoid this type 1 error inflation problem: family wise error rate (FWER) control (Bonferroni, 1936) and false discovery rate (FDR) control (Benjamini and Hochberg, 1995) . Here, in order to overcome the multiple comparison problem, we extend our method for computing the sample size with controlling FDR and FWER.
In addition, our sample size calculation program proposed here, available at http://statgen.snu.ac.kr/cosmos, can be used in the graphical user interface. It yields the needed sample size and graph of the power function with only a few input parameters.
Methodology
In this section, a LMM model is first introduced to analyse the data attained from CDs. Second, an appropriate hypothesis and corresponding test statistic are proposed. Third, we propose a new method for determining the sample size for each sequence in CDs. Finally, in order to tackle the multiple comparison problem, we derive a method for determining the sample size while controlling FDR and FWER. Bonferroni correction is used to control FWER because it is the most conservative method for this purpose (Bonferroni, 1936) . The procedure proposed by Benjamini and Hochberg (1995) is used to control FDR because it is known to be the most conservative method for doing so (Storey et al., 2004) .
Linear mixed model
We assume that there are K groups and J sequences with K periods in the CDs. Let n represent the sample size needed for each sequence. Let , 1, , ,
, denote a response value for the i-th subject at the K-th period in the jth sequence, ij X be the design matrix for the i-th subject in the j-th sequence, and ij Z be the design matrix for i-th subject in the j-th sequence for a random effect. For the orthogonal CDs, the following LMM can be applied:
; unit vector with K length. Note that ij X can be defined by the design. Considering the orthogonal CD with three treatments given in Table 1 , ij X is defined as follows: 
where I is an identity matrix. The variance of ij y can be obtained
Note that the variability of response values is accounted for by between-subject and within-subject variation.
Parameter estimation
The parameters β , 2 σ intra , and 2 σ inter can be estimated by maximising the restricted likelihood (Patterson and Thompson, 1971) . The estimators maximising the restricted log-likelihood function are referred to as the restricted maximum likelihood estimator (REML). REML can be obtained by a two-step procedure. First, the variance components  . This following two-step procedure needs to be iterated until convergence.
The log-likelihood is given by
If we maximise log-likelihood (2) for a fixed V with respect to β , we get
The log-likelihood with  β plugged is called profile log-likelihood. The restricted log-likelihood (4) is defined by log-likelihood for marginal distribution of V :
Restricted log-likelihood (4) can also be expressed by the profile log-likelihood:
The variance components can then be estimated by maximising the restricted log-
V into  β , the fixed effects parameter β can be estimated as
Next β is plugged into r l , and  ij V again can be estimated. These steps are repeated until convergence.
Statistical test statistic and power function
The goal of CD is to determine whether a statistically significant mean difference among groups exists or not. The null and alternative hypotheses for testing mean difference among groups are given as follows:
The Wald type test statistic is given by
where L is the contrast matrix and r is the rank of L . For hypothesis test (5) 
Thus, the power function of this test is given by 
Sample size calculation for a single biomarker
In order to determine the sample size, we first have to fix a significance level such as  and to decide the desired power. and the non-central parameter  . We can compute the optimal sample size n for each sequence by solving the following equation (7) numerically:
Sample size calculation for multiple biomarkers after controlling the family wise error rate
When M biomarkers are available in one experiment, we need to carry out M statistical tests simultaneously to find candidate biomarkers. If we reject a null hypothesis when the p-value is less than the significant level  , then the overall type 1 error becomes inflated (Wang and Chow, 2007) . To handle this multiple testing problem, either FDR or FWER control has been widely used. Here, we propose two methods for sample size computation: one using Bonferroni correction to control the FWER and the other controlling the FDR. In this section, we first treat the case of controlling FWER via Bonferroni correction. Suppose that we perform the M tests of 
Sample size calculation for multiple biomarkers after controlling the false discovery rate
Now, we describe how to compute the sample size while controlling FDR. Without loss of generality, we assume that there are M tests as in (8). For computational convenience, we also assume the equal treatment effect for M biomarkers. The results of M multiple tests can be summarised as shown in Table 3 . In multiple hypothesis testing via controlling the FDR, we can consider   1 1 / E R m the desired power of a conventional test (Lee and Whitmore, 2002) . Setting   1 E R and the FDR level as  and  , the FDR can be expressed as
by Jung (2005) . By solving (10) with respect to α and letting
where
 means a significance level  controlling FDR at  . For the given total number of biomarkers M, the number of prognostic markers 1 m , and the desired power with the FDR  , the sample size can be computed by solving the following equation (12) numerically: 
An example
Here we illustrate our proposed method for determining sample size with an example experiment being conducted in the Department of Nutritional Science and Food Management at Ewha Womans University. The experiment involved evaluating effects of ingesting platycodi ratix water on postprandial triglycerides. The major goal of the study is to determine whether any lipodomic differences exist among placebo (P), lowdose (L), and high dose (H) groups. To do so, the orthogonal CD was used with three groups and six sequences of PLH, PHL, HPL, HLP, LPH, and LHP (Figure 1 ). For each sequence, 6n subjects were randomly allocated to maintain a balance. In order to determine the optimal sample size, one first needs to assume the group effect sizes. However, as there had been no pilot study, the results in Gutiérrez-Salmeán et al. (2014) were used, in which the triglyceride level means in blood 2 hours after a meal were 120.0, 110.0, and 100.0 mg/dL for P, L, and H groups, respectively. Under the assumption of homoscedasticity, the common variation was set at 400.0 mg/dL. Using the group effect size and common variation, we determined the sample size at the significance level and desired power to set at 0.05 and 0.8, respectively. Anticipating issues, we also assumed a 20% drop-out rate. In addition, to illustrate computation of the sample size controlling the FWER via Bonferroni correction, we assumed that 100 biomarkers would be measured. To calculate the sample size controlling FDR at 0.01, we assumed that there were 10 prognostic biomarkers among the 100 biomarkers measured. 
From (13), the variation for response variable is the summation of between-subject and within-subject variations. Since we assume the common variation 2  to be 400.0, sample sizes are determined by setting the contribution of between-subject to the total variation at 70%, 50%, and 30%. Table 4 is the result of determining the sample sizes, where sample size( nd ) means the sample sizes reflected a 20% dropout rate. As the sample size increases, the contribution of within-subject variation tends to increase. In other words, the contribution of between-subject variation decreases. This in turn causes the loss of information from subjects. Thus, the computed sample size results seem reasonable. 
